Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

The healthcare sector, particularly pharmaceuticals and hospitals, have demonstrated strong performance in the March 2025 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

These five well-run companies with stocks that yield at least 5% have strong dividend coverage and look like timely buys now.

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

This Big Pharma company is positioned for a rebound while continuing to pay investors a sizable dividend yield.

Shares of Dr Reddy's Laboratories decreased by 2 per cent to Rs 1,317 in morning trading, following Citi Research's decision ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...